Tumor Biology

, Volume 35, Issue 9, pp 9053–9059 | Cite as

TPM3, a strong prognosis predictor, is involved in malignant progression through MMP family members and EMT-like activators in gliomas

  • Tao Tao
  • Yan Shi
  • Dongfeng Han
  • Wenkang Luan
  • Jin Qian
  • Junxia Zhang
  • Yingyi Wang
  • Yongping You
  • Chinese Glioma Cooperative Group (CGCG)
Research Article


Recent studies have shown that many molecular mechanisms, such as the EGFR, AKT, STAT3, and beta-catenin pathways, are involved in glioma. However, the prognosis of the disease remains poor. Explorations of the underlying mechanisms of glioma and identification of effective markers for early diagnosis and accurate prognostication remain important today. In this study, we employed survival analysis to determine that TPM3 overexpression was significantly associated with high-grade gliomas and higher mortality. Using microarray combined with Pearson correlation analysis, we found that TPM3 was positively correlated with the expression of MMP family members and EMT-like activators. Reduction of TPM3 (via TPM3-siRNA) inhibited cellular invasion and migration and decreased MMP-9 and SNAI1 levels in glioma cells. To the best of our knowledge, our work is the first to show that TPM3 plays a critical role in the progression of gliomas and provides novel insights into the key roles of MMP family members and EMT-like activators that mediate TPM3 functional signaling for glioma regulation.


TPM3 MMP-9 SNAI1 Invasion Migration EMT Survival Glioma 



This work was supported by grants from the National High Technology Research and Development Program of China (863) (2012AA02A508), International Cooperation Program (2012DFA30470), National Natural Science Foundation of China (91229121, 81272792, 81172389,81372709, 81302185, 81101901,81302184), Jiangsu Province’s Natural Science Foundation (BK2011847 and 20131019), Jiangsu Province’s Key Provincial Talents Program (RC2011051), Jiangsu Province’s Key Discipline of Medicine (XK201117), Jiangsu Provincial Special Program of Medical Science (BL2012028), and Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU, and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Conflicts of interest


Supplementary material

13277_2014_1974_Fig6_ESM.gif (13 kb)
Supplementary Fig.1

Cell proliferation determined by CCK-8 assay. (A and B) CCK-8 assays showed that there was no significant difference between si-TPM3-transfected cells and negative control group within 24 hours. #P > 0.05. Results were presented as mean±SD from three independent experiments. (GIF 12 kb)

13277_2014_1974_MOESM1_ESM.tif (1.7 mb)
High resolution image (TIFF 1740 kb)
13277_2014_1974_Fig7_ESM.gif (94 kb)
Supplementary Fig.2

MMP-9 and SNAI1 involved in TPM3 functional signaling for glioma invasion and migration. (A and B) si-MMP9 and si-SNAI1 were introduced into TPM3-treated cells. Decreased MMP9 or SNAI1 in TPM3-treated cells rescued the invasion phenotype induced by TPM3. (C and D) Introduction of si-MMP9 or si-SNAI1 abrogated TPM3 overexpression-induced cellular migration. (*P < 0.05, **P < 0.01). Results were presented as mean±SD from three independent experiments. (GIF 93 kb)

13277_2014_1974_MOESM2_ESM.tif (1.7 mb)
High resolution image (TIFF 1691 kb)


  1. 1.
    Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331:139–46.CrossRefPubMedGoogle Scholar
  2. 2.
    Pieples K, Arteaga G, Solaro RJ, et al. Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca(2+) activation. Am J Physiol Heart Circ Physiol. 2002;283:H1344–53.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282:14328–36.CrossRefPubMedGoogle Scholar
  4. 4.
    Kim TM, Yim SH, Shin SH, et al. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer. 2008;123:2808–15.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Miyado K, Kimura M, Taniguchi S. Decreased expression of a single tropomyosin isoform, TM5/TM30nm, results in reduction in motility of highly metastatic B16-F10 mouse melanoma cells. Biochem Biophys Res Commun. 1996;225:427–35.CrossRefPubMedGoogle Scholar
  6. 6.
    Yan W, Zhang W, You G, et al. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol. 2012;14:1432–40.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Zhang C, Zhang J, Hao J, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med. 2012;10:119.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Choi HS, Yim SH, Xu HD, et al. Tropomyosin3 overexpression and a potential link to epithelial–mesenchymal transition in human hepatocellular carcinoma. BMC Cancer. 2010;10:122.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Brabletz T, Jung A, Reu S, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98:10356–61.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 2013;331:131–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Brabletz T. To differentiate or not—routes towards metastasis. Nat Rev Cancer. 2012;12:425–36.CrossRefPubMedGoogle Scholar
  12. 12.
    Elias MC, Tozer KR, Silber JR, et al. TWIST is expressed in human gliomas and promotes invasion. Neoplasia. 2005;7:824–37.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Qi S, Song Y, Peng Y, et al. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One. 2012;7:e38842.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.CrossRefPubMedGoogle Scholar
  15. 15.
    Bhat-Nakshatri P, Appaiah H, Ballas C, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24− phenotype. BMC Cancer. 2010;10:411.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Han SP, Kim JH, Han ME, et al. SNAI1 is involved in the proliferation and migration of glioblastoma cells. Cell Mol Neurobiol. 2011;31:489–96.CrossRefPubMedGoogle Scholar
  17. 17.
    Weissenberger J, Priester M, Bernreuther C, et al. Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin Cancer Res. 2010;16:5781–95.CrossRefPubMedGoogle Scholar
  18. 18.
    Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Surgucheva I, Chidambaram K, Willoughby DA, Surguchov A. Matrix metalloproteinase 9 expression: new regulatory elements. J Ocul Biol Dis Infor. 2010;3:41–52.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.CrossRefPubMedGoogle Scholar
  21. 21.
    Comincini S, Paolillo M, Barbieri G, et al. Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. J Biomed Biotechnol. 2009;2009:924565.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Yan W, Zhang W, Sun L, et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res. 2011;1411:108–15.PubMedGoogle Scholar
  23. 23.
    Liu Z, Li L, Yang Z, et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Chu D, Zhang Z, Li Y, et al. Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer. 2011;129:887–95.CrossRefPubMedGoogle Scholar
  25. 25.
    Offersen BV, Knap MM, Horsman MR, Verheijen J, Hanemaaijer R, Overgaard J. Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol. 2010;49:1283–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Tao Tao
    • 1
    • 2
  • Yan Shi
    • 1
  • Dongfeng Han
    • 1
  • Wenkang Luan
    • 1
  • Jin Qian
    • 1
    • 3
  • Junxia Zhang
    • 1
  • Yingyi Wang
    • 1
  • Yongping You
    • 1
  • Chinese Glioma Cooperative Group (CGCG)
  1. 1.Department of NeurosurgeryFirst Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  2. 2.Surgical Research Center, Medical SchoolSoutheast UniversityNanjingChina
  3. 3.Department of NeurosurgeryPeople’s Hospital of Xuancheng CityAnhuiChina

Personalised recommendations